Congratulations to Lauren Mihalcik on Election to the ACT Council
Please join us in congratulating Lauren Mihalcik, PhD, DABT on being elected to the Council of the American College of
Company News
Scientific Perspectives
Moving Beyond the NAMs vs. Animals Narrative in Pharmaceutical Development
As part of an effort to reframe the prevailing narrative of NAMs as a replacement for animals towards one of
Conference Presentations, Regulatory Insights
ACT Signature Webinar (Delivered 9/2/2026)
Weight of Evidence Approaches for DART Assessments of Oligonucleotides: Current Reality and Future Considerations This presentation focuses on the regulatory
ACT
Meet us in San Antonio – Nov 15-18, 2026 Learn more about ACT 2026: actox.org/am/am2026/
Scientific Perspectives, Uncategorized
Safety considerations for cereblon-recruiting targeted protein degraders
Aclairo’s Ron Wange and the HESI Targeted Protein Degrader Safety Group recently published a review of key safety issues with
Featured
Rethinking Clinical Trials for Pregnant and Breastfeeding Patients
Pregnant and breastfeeding individuals have long been excluded from clinical drug development, leaving physicians and patients to make critical treatment
Expert Insights
Advancing Treg Cell Therapy
Uyen Dinh, PhD and I were delighted to be asked to contribute to a special edition of Frontiers in Immunology
Uncategorized
SOT 65th Annual Meeting
EPL and Aclairo Pharmaceutical Development Group, Inc. are looking forward to seeing everyone at the SOT 65th Annual Meeting in
Featured
FDA Gene Editing Guidance
FDA has issued a new gene editing guidance that gives additional information on expectations for use of next-generation sequencing. The
Uncategorized
HESI Targeted Protein Degrader Safety Group
Aclairo’s Ron Wange and the HESI Targeted Protein Degrader Safety Group recently published a review of key safety issues with